Pradžia › Berkito limfoma
Berkito limfoma klinikiniai tyrimai JAV ieško dalyvių
63 tyrimai dėl Berkito limfoma ieško dalyvių vietose visoje Jungtinėse Valstijose.
Miestai su daugiausia tyrimų
- Houston, TX21 tyrimas
- Milwaukee, WI16 tyrimai
- Philadelphia, PA16 tyrimai
- New York City, NY14 tyrimai
- Chicago, IL14 tyrimai
- Cincinnati, OH12 tyrimai
- Atlanta, GA12 tyrimai
- Seattle, WA11 tyrimai
- Boston, MA10 tyrimai
- Durham, NC10 tyrimai
- Los Angeles, CA10 tyrimai
- Aurora, CO10 tyrimai
- Kansas City, MO10 tyrimai
- Orange, CA9 tyrimai
- Washington, DC9 tyrimai
- Minneapolis, MN9 tyrimai
- Baldwin Park, CA9 tyrimai
- Portland, OR8 tyrimai
- Buffalo, NY8 tyrimai
- Columbus, OH8 tyrimai
- Ann Arbor, MI8 tyrimai
- Nashville, TN8 tyrimai
- Baltimore, MD8 tyrimai
- San Francisco, CA8 tyrimai
- Tampa, FL7 tyrimai
- Dallas, TX7 tyrimai
- Clifton, NJ7 tyrimai
- Providence, RI7 tyrimai
- Greenburgh, NY7 tyrimai
- Birmingham, AL7 tyrimai
- Grand Rapids, MI7 tyrimai
- San Antonio, TX7 tyrimai
- Richmond, VA7 tyrimai
- Cleveland, OH7 tyrimai
- Salt Lake City, UT7 tyrimai
- Oklahoma City, OK7 tyrimai
- Jacksonville, FL7 tyrimai
- The Bronx, NY6 tyrimai
- Mountain View, CA6 tyrimai
- St. Petersburg, FL6 tyrimai
Pagal valstiją
- Aidahas6 tyrimai
- Ajova7 tyrimai
- Alabama7 tyrimai
- Arizona7 tyrimai
- Arkansas5 tyrimai
- Delaveras7 tyrimai
- Džordžija12 tyrimai
- Florida15 tyrimai
- Havajai5 tyrimai
- Ilinoisas14 tyrimai
- Indianas6 tyrimai
- Kalifornija20 tyrimai
- Kanzasas6 tyrimai
- Kentukis5 tyrimai
- Koloradas13 tyrimai
- Kolumbijos apskritis5 tyrimai
- Konektikutas7 tyrimai
- Luiziana4 tyrimai
- Masčusetsas10 tyrimai
- Menas4 tyrimai
- Merilendas11 tyrimai
- Minesota10 tyrimai
- Misisipė4 tyrimai
- Misūris8 tyrimai
- Mičiganas10 tyrimai
- Naujoji Hampšyras4 tyrimai
- Nebraska5 tyrimai
- Nevada6 tyrimai
- New Jersey8 tyrimai
- New Mexico3 tyrimai
- New York20 tyrimai
- North Carolina13 tyrimai
- North Dakota5 tyrimai
- Ohio17 tyrimai
- Oklahoma7 tyrimai
- Oregon8 tyrimai
- Pennsylvania18 tyrimai
- Rhode Island7 tyrimai
- South Carolina5 tyrimai
- South Dakota5 tyrimai
- Tennessee10 tyrimai
- Texas24 tyrimai
- Utah7 tyrimai
- Vermont3 tyrimai
- Virginia7 tyrimai
- Washington11 tyrimai
- West Virginia3 tyrimai
- Wisconsin17 tyrimai
Nesenai atnaujinti tyrimai
Oficialus tyrimo tekstas (anglų kalba)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Renkami dalyviai2 fazė
366 Days – 46 Years · Visoms lytims · Atnaujinta 2026-10-02 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Renkami dalyviai3 fazė
Amžius nuo 18 iki 39 · Visoms lytims · Atnaujinta 2026-10-02 · NCT03150693Blinatumomab Consolidation in Real World
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT07117136Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 0 iki 38 · Visoms lytims · Atnaujinta 2026-10-01 · NCT06131801CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Renkami dalyviai1/2 fazė
Amžius nuo 3 iki 39 · Visoms lytims · Atnaujinta 2026-09-30 · NCT05442515Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-29 · NCT03739814Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 120 · Visoms lytims · Atnaujinta 2026-09-28 · NCT03223610Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06144606Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Renkami dalyviai2 fazė
365 Days · Visoms lytims · Atnaujinta 2026-09-25 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-21 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Renkami dalyviai3 fazė
Amžius 1 ir vyresni · Visoms lytims · Atnaujinta 2026-09-17 · NCT07223021Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Renkami dalyviai1/2 fazė
6 Months – 25 Years · Visoms lytims · Atnaujinta 2026-09-17 · NCT06395103A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Renkami dalyviai1 fazė
Amžius nuo 0 iki 18 · Visoms lytims · Atnaujinta 2026-09-16 · NCT06173518UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
Renkami dalyviai1/2 fazė
31 Days – 30 Years · Visoms lytims · Atnaujinta 2026-09-14 · NCT04544592Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-08 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Renkami dalyviai2 fazė
Amžius nuo 1 iki 30 · Visoms lytims · Atnaujinta 2026-09-01 · NCT04546399Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Renkami dalyviai1 fazė
Amžius nuo 18 iki 120 · Visoms lytims · Atnaujinta 2026-08-25 · NCT05389423Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Renkami dalyviai3 fazė
365 Days – 25 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT03959085Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-19 · NCT06710418Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Renkami dalyviai2 fazė
Amžius nuo 7 iki 25 · Visoms lytims · Atnaujinta 2026-08-19 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Renkami dalyviai1/2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-08-19 · NCT06137118AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-12 · NCT06340737Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-10 · NCT06287229Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Renkami dalyviai2 fazė
Amžius 15 ir vyresni · Visoms lytims · Atnaujinta 2026-08-10 · NCT03136146Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Renkami dalyviai1/2 fazė
Amžius nuo 13 iki 90 · Visoms lytims · Atnaujinta 2026-08-06 · NCT06533579Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.